Drugs / DNA-HIV-PT123

Trials 10

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT04844775 Aug 2022 → Sep 2024 — ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 1 NCT04842682 Mar 2021 → Nov 2024 — ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 1 NCT03391375 Mar 2017 → Jan 2018 HIV infectious disease EuroVacc Foundation Completed No outcome recorded
Phase 1 NCT02376582 Sep 2014 → Jan 2016 HIV infectious disease EuroVacc Foundation Completed No outcome recorded
Phase 1 NCT02207920 Jul 2014 → Dec 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01783977 Apr 2013 → Sep 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01799954 Aug 2012 → Dec 2014 HIV infectious disease HIV Vaccine Trials Network Completed No outcome recorded
Phase 1 NCT01927835 ? → Jan 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 1 NCT01964937 ? → Apr 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 21 trial
Phase 2 NCT04066881 Dec 2020 → Dec 2024 HIV infectious disease MRC/UVRI and LSHTM Uganda Research Unit Completed No outcome recorded
Comparator or background therapy1 trial
Phase 1 NCT02997969 Comparator Jun 2016 → Jul 2018 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as DNA-HIV-PT123 “The proposed vaccine trial will generate safety, tolerability and immunogenicity data of a vaccination regimen with simultaneous administration of a candidate HIV DNA vaccine...” NCT02376582 ↗
10

“combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24” NCT04842682 ↗

NCT01799954 ↗

NCT02997969 ↗

NCT02207920 ↗

NCT01927835 ↗

NCT01783977 ↗

NCT04844775 ↗

NCT01964937 ↗

NCT03391375 ↗

NCT04066881 ↗

Modality Vaccine “DNA HIV vaccine” NCT01783977 ↗
Route Intramuscular “administered as 1 mL IM in participant's deltoid” NCT01783977 ↗